Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.84 +0.23 (+1.47%)

Streaming Delayed Price Updated: 12:55 PM EDT, Jul 6, 2026 Add to My Watchlist

Price and Volume

Volume	380,068
Open	15.82
Bid (Size)	15.84 (400)
Ask (Size)	15.85 (300)
Prev. Close	15.61
Today's Range	15.48 - 15.95
52wk Range	7.360 - 19.25
Shares Outstanding	128,395,927
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Today 8:00 EDT

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating ↗

June 16, 2026

Via Chartmill

Performance

YTD	+3.2%	+3.2%
1 Month	+0.0%	+0.0%
3 Month	-1.0%	-1.0%
6 Month	+3.5%	+3.5%
1 Year	+112.0%	+112.0%

More News

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million ↗

June 07, 2026

Via The Motley Fool

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

June 04, 2026

From Aurinia Pharmaceuticals Inc.

Via Business Wire

AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Screens Strong on Minervini Trend Template and High Growth Momentum ↗

May 01, 2026

Via Chartmill

AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH): A High-Growth Momentum and Technical Trend Case Study ↗

March 27, 2026

Via Chartmill

Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences

May 19, 2026

Via Newsfile

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

May 07, 2026

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

March 30, 2026

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Announces Management Transition

March 23, 2026

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Key Growth Screener from "The Little Book That Makes You Rich" ↗

March 03, 2026

Via Chartmill

Aurinia Pharmaceuticals (NASDAQ:AUPH) Beats Q4 2025 Estimates and Provides 2026 Guidance ↗

February 26, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗

February 26, 2026

Via Stocktwits

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

February 26, 2026

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

February 19, 2026

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗

December 02, 2025

Via The Motley Fool

AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen ↗

November 07, 2025

Via Chartmill

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

November 04, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

A Peek at Aurinia Pharmaceuticals's Future Earnings ↗

November 03, 2025

Via Benzinga

FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse ↗

November 03, 2025

Via Benzinga

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

November 03, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗

November 02, 2025

Via Stocktwits

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis ↗

October 17, 2025

Via Chartmill

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

October 15, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Frequently Asked Questions

Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?

Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.

What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?

Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?

The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market

What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?

The current price of Aurinia Pharmaceuticals Inc - Common Shares is 15.84

When was Aurinia Pharmaceuticals Inc - Common Shares last traded?

The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 07/06/26 12:55 PM ET

What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?

The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 2.03B

How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?

Aurinia Pharmaceuticals Inc - Common Shares has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.